What is the effect of systemic anticancer treatment on cognitive function? (Q35761681)

10 August 2017

1 reference

title

What is the effect of systemic anticancer treatment on cognitive function? (English)

1 reference

10 August 2017

3

Andrew Bottomley

1 reference

10 August 2017

Alessandro Minisini

1

1 reference

10 August 2017

Gul Atalay

2

1 reference

10 August 2017

Fabio Puglisi

4

1 reference

10 August 2017

Martine Piccart

5

1 reference

10 August 2017

Laura Biganzoli

6

1 reference

10 August 2017

publication date

1 May 2004

1 reference

Lancet Oncology Commission

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

273-282

1 reference

Cytokine-associated emotional and cognitive disturbances in humans

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive functioning in cancer patients: effect of previous treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Serial cognitive testing in cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive deficits in patients with small cell lung cancer before and after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Follow-up of cognitive functioning in patients with small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Sequelae in long-term survivors of small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neurological and cognitive impairment in long-term survivors of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neuropsychological evaluation of patients with inoperable non-small cell lung cancer treated with combination chemotherapy or radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Can older cancer patients tolerate chemotherapy? A prospective pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Novel effects of estradiol and estrogen receptor alpha and beta on cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

17beta-estradiol enhances cortical cholinergic innervation and preserves synaptic density following excitotoxic lesions to the rat nucleus basalis magnocellularis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Localization of androgen receptor within peptidergic neurons of the rat forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Effects of gonadectomy on immunoreactivity for choline acetyltransferase in the cortex, hippocampus, and basal forebrain of adult male rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

The effects of tamoxifen and estrogen on brain metabolism in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive function effects of suppressing ovarian hormones in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive function in postmenopausal women treated with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Cognitive function and quality of life in interferon therapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Expression of the EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Regulation of neuregulin expression in the injured rat brain and cultured astrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

Group cognitive behavioural therapy interventions with cancer patients: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901465-2

7 January 2021

10.1016/S1470-2045(04)01465-2

Identifiers

DOI

1 reference

10 August 2017

1 reference